Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M31.2Revenue (TTM) $M0.1Net Margin (%)-10,256.6Altman Z-Score-15.4
Enterprise Value $M23.3EPS (TTM) $-0.1Operating Margin %-11,327.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-10,256.6Higher ROA y-yY
Price/Book1.810-y EBITDA Growth Rate %-9.8Quick Ratio2.7Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-11.0Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-53.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-60.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M248ROIC % (ttm)-143.0Gross Margin Increase y-yN

Gurus Latest Trades with HEB

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

HEB is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Equels Thomas K.CEO, President 2016-07-08Buy48,000$0.128.33view
Equels Thomas K.CEO,President 2016-07-01Buy171,000$0.128.33view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-18Buy30,000$0.130view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-11Buy40,000$0.16-18.75view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-11Buy40,000$0.16-18.75view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-10Buy30,000$0.16-18.75view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-10Buy30,000$0.16-18.75view
CARTER WILLIAM ACEO, 10% Owner 2015-08-20Buy25,000$0.18-27.78view
CARTER WILLIAM ACEO, 10% Owner 2015-08-18Buy25,000$0.18-27.78view
CARTER WILLIAM ACEO, 10% Owner 2015-08-17Buy25,000$0.18-27.78view

Quarterly/Annual Reports about HEB:

News about HEB:

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe Jul 25 2016
Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe Jul 25 2016
Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and... Jul 19 2016
Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency Jul 14 2016
Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency Jul 14 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 11 2016
Hemispherx Updates the Status of the Alferon® Manufacturing Facility Jul 11 2016
Hemispherx Updates the Status of the Alferon® Manufacturing Facility Jul 11 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 20 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 10 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 08 2016
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative... Jun 08 2016
Hemispherx gets IP rights from the CEO it fired Jun 07 2016
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in... Jun 07 2016
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod... Jun 07 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events Jun 06 2016
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property Jun 06 2016
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property Jun 06 2016
Early Morning Technical Highlights on Biotech Stocks May 31 2016
Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm May 31 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)